Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Sunday, April 17<br />
Poster Session 8:30 a.m.–5:30 p.m.<br />
P2.068 Teriflunomide Mechanism of<br />
Action: Linking Species’ Sensitivities to<br />
Pregnancy Outcomes —Lynn Davenport,<br />
Andrea Edling, Patrick Finn, Philippe Truffinet,<br />
Steve Cavalier<br />
P2.069 Real-World Safety and Efficacy<br />
of Natalizumab After Switching from<br />
Other Disease-Modifying Therapies<br />
(DMTs): Data from the Tysabri ®<br />
Observational Program (TOP)—Helmut<br />
Butzkueven, Ludwig Kappos, Maria Trojano,<br />
Heinz Wiendl, Radhika Patel, Harold<br />
Koendgen, Cynthia Carrillo-Infante, Yi Chen,<br />
Pei-Ran Ho, Nolan Campbell<br />
P2.070 Safety of Teriflunomide<br />
in Multiple Sclerosis Treatment.<br />
Management of Hepatic Disorders in Real<br />
World Experience —Jose E Meca-Lallana,<br />
Rocío Hernández-Clares, Ester Carreón-<br />
Guarnizo, María Cerdan-Sanchez, Cristina<br />
Sánchez-Vizcaíno Buendía, Judith Jimenez-<br />
Veiga, Gema Salgado-Cecilia, Adelaida Leon-<br />
Hernández, Jose Javier Martín-Fernández<br />
P2.071 Altered Objective Exertion<br />
Tolerance in MS Patients Treated with<br />
Fingolimod: A Prospective, Longitudinal<br />
Ergospirometry Study —Christoph Mayer,<br />
Hanna Schnitzbauer, Christine Schuhmann,<br />
Ulf Ziemann<br />
P2.072 Fingolimod Suppresses Bone<br />
Resorption in Patients with Multiple<br />
Sclerosis —Yusei Miyazaki, Masaaki Niino,<br />
Ippei Kanazawa, Masako Suzuki, Masanori<br />
Mizuno, Shin Hisahara, Toshiyuki Fukazawa,<br />
Eri Takahashi, Itaru Amino, Ryutaro Ochi,<br />
Naoya Minami, Naoto Fujiki, Shizuki Doi, Seiji<br />
Kikuchi<br />
P2.073 Natalizumab<br />
Associated Progressive Multifocal<br />
Leukoencephalopathy: Successful<br />
Treatment Without Plasmaexchange and<br />
Its Associated Risks —Eimer Maloney,<br />
Anna Molloy, Mariam Al Hussona, Luke<br />
O'Donnell, Ronan Killeen, Christopher<br />
McGuigan<br />
P2.074 Rapid-Onset Immune<br />
Thrombocytopenia Following<br />
Alemtuzumab Treatment in Relapsing,<br />
Remitting Multiple Sclerosis —Mark<br />
Obermann<br />
P2.075 Progressive Multifocal<br />
Leukoencephalopathy in the Setting of<br />
Idiopathic CD4 Lymphocytopenia: Case<br />
Report and Literature Review of the<br />
Epidemiology —Tareq Yaqub, Talal Derani,<br />
Tariq Gheith, Rany Aburashed<br />
P2.076 Cardiac Safety Profile of the<br />
First Dose Observation. Interim Analysis<br />
of the Argentinean Registry of Patients<br />
Treated with Fingolimod (REAL Study) —<br />
Gustavo Seifer, Fernando Caceres, Marcela<br />
Parada Marcilla, Vladimiro Sinay, Miguel<br />
Jacobo, Roberto Rey, Maria Saladino, Andres<br />
Villa, Marcos Burgos, Norma Deri, Rossana<br />
Neme, Graciela Arguello De Alday, Jose<br />
Maria Blasco, Patricio Labal, Christian Calvo<br />
Vildoso, Santiago Vetere, Gabriel Volman,<br />
Carlos Ballario, Jorge Blanche, Marcelo<br />
Matiazzi, Alberto Rodriguez Alfici, Herrera<br />
Gustavo, Ramiro Linares, Virginia Laura Parisi,<br />
Andres Barboza, Pedro Nofal, Margarita<br />
Moreno, Albornoz Liliana, Gaston Kuperman,<br />
Andres Greco<br />
P2.077 4 Years Safety of<br />
Fingolimod in Real World: PANGAEA,<br />
a Non-Interventional Study of Safety,<br />
Effectiveness and Pharmacoeconomic<br />
Data for Fingolimod Patients in Daily<br />
Clinical Practice —Tjalf Ziemssen, Holger<br />
Albrecht, Judith Haas, Luisa Klotz, Michael<br />
Lang, Chrstoph Lassek, Stephan Schmidt,<br />
Bjorn Tackenberg, Christian Cornelissen<br />
P2.078 Dimethyl Fumarate (DMF)-<br />
Induced Necrotizing Myopathy: A<br />
Case Report —Charlotte Zisman, Emiliya<br />
Melkumova, Jin Li<br />
P2.079 Rebound Syndrome in Multiple<br />
Sclerosis Patients After Cessation of<br />
Fingolimod —Stacy Hatcher, Emmanuelle<br />
Waubant, Bardia Nourbakhsh, Elizabeth<br />
Crabtree-Hartman, Jennifer Graves<br />
P2.080 Effect of Siponimod Treatment<br />
on Vaccination-Induced Immune<br />
Response: A Randomized, Double-Blind,<br />
Placebo-Controlled Study —Mike Ufer,<br />
Kiran Dole, Jude Ngang, Anne Gardin,<br />
Zhenzhong Su, Swathi Peteri, Kasra Shakeri-<br />
Nejad, Eric Legangneux<br />
P2.081 Rebound of Disease Activity<br />
After Fingolimod Discontinuation: Report<br />
of Six Cases —Aksel Siva, Ugur Uygunoglu,<br />
Melih Tutuncu, Ayse Altintas, Sabahattin Saip<br />
P2.082 Longterm Fingolimod<br />
Treatment of Multiple Sclerosis Induces<br />
Phenotypical Immunsenescence —Nicole<br />
Schwanitz, Andreas Boldt, Muriel Stoppe,<br />
Johannes Orthgiess, Stefan Borte, Ulrich<br />
Sack, Florian Then Bergh<br />
P2.083 Experience with Serious<br />
Cutaneous Events in the DECIDE Study —<br />
Corey Ford, Bhupendra Khatri, Tomas Olsson,<br />
Tjalf Ziemssen, Xiaojun You, Wanda Castro-<br />
Borrero, Peter McCroskery<br />
P2.084 Disease Course in Elderly MS<br />
Patients —Florian Deisenhammer, Felix<br />
Bayer, Gabriel Bsteh, Michael Auer, Franziska<br />
Di Pauli, Harald Hegen, Thomas Berger<br />
P2.085 The Prevalence of a History<br />
of Prior VZV/HZV Infection in MS: A<br />
Survey Study with Serological Validation<br />
Sub-Study —Cris Constantinescu, Ali<br />
Manouchehrinia, Radu Tanasescu, Huner<br />
Kareem, Oltita Jerca, William Irving<br />
P2.086 Incidence and Timing of<br />
Thyroid Adverse Events in Patients<br />
with RRMS Treated with Alemtuzumab<br />
Through 5 Years of the CARE-MS<br />
Studies —Peter Senior, Douglas Arnold,<br />
Jeffrey Cohen, Edward Fox, Hans-Peter<br />
Hartung, Eva Havrdova, Krzysztof Selmaj,<br />
David Margolin, Linda Kasten, Alasdair Coles<br />
P2.087 Immunogenicity with Repeated<br />
Dosing of Ocrelizumab in Patients with<br />
Multiple Sclerosis —An Song, Robert<br />
Hendricks, Shan Chung, Qing Wang, Peter<br />
Chin, Hideki Garren<br />
P2.088 Is Aging and<br />
Immunosenescence a Risk Factor For<br />
Dimethyl Fumarate Induced PML? —John<br />
Foley, Angelene Christensen, Tamara Hoyt,<br />
Angela Foley, Ryan Metzger<br />
P2.089 The Effects of High Dose<br />
Corticosteroids for MS Relapse on Blood<br />
Pressure: A Pilot Study —Ryan Renn,<br />
George Dresser, Sarah Morrow<br />
P2.090 First-Dose Effects of<br />
Fingolimod in Patients with RRMS<br />
Receiving Concomitant SSRIs on Day<br />
1: Pooled Analysis of the Real-World<br />
PREFERMS and EPOC Studies —Bruce<br />
Hughes, Mark Cascione, Edward Fox, Xiangyi<br />
Meng, Brandon Brown<br />
P2.091 Cytomegalovirus Reactivation<br />
During Alemtuzumab Treatment for<br />
Multiple Sclerosis: A Case Report —<br />
Stefania De Mercanti, Luca Durelli, Marco<br />
Iudicello, Carlo Alberto Artusi, Pierangelo<br />
Barbero, Angelo Guerrasio, Marinella Clerico<br />
P2.092 Clinical Safety of the Novel,<br />
Selective S1P Receptor Modulator,<br />
Ozanimod, from Phase 2 Trials in<br />
Relapsing Multiple Sclerosis (RADIANCE)<br />
and Moderate to Severe Ulcerative Colitis<br />
(TOUCHSTONE)—Paul Frohna, Allan Olson,<br />
Matthew Cravets, Jeffrey Hartung, Heather<br />
Smith, Richard Aranda, Sheila Gujrathi<br />
P2.093 NMDA Receptor Encephalitis<br />
in an MS Patient on Fingolimod —Rebecca<br />
Straus Farber, Elina Zakin, Aaron Miller<br />
P2.094 PML-IRIS Associated with<br />
Fingolimod in a Multiple Sclerosis Patient<br />
with Prior Immunosuppression —Tirisham<br />
Gyang, Johanna Hamel, Andrew Goodman,<br />
Lawrence Samkoff<br />
P2.095 Case Report: Atypical<br />
Presentation of PML in a Patient with<br />
Alcoholic Cirrhosis —Nassima Baba-<br />
Ahmed, Robert Neel<br />
P2.096 Reversal of Relapse Pattern<br />
During Pregnancy in Women Treated with<br />
Natalizumab Up to Pregnancy —Charlotte<br />
Spicher, Sandra Thiel, Renate Klaaßen-<br />
Mielke, Katja Brandau, Ralf Gold, Kerstin<br />
Hellwig<br />
P2.097 Delayed-Release Dimethyl<br />
Fumarate Does Not Adversely Affect the<br />
Pharmacokinetics of a Commonly Used<br />
Oral Contraceptive (Norgestimate/Ethinyl<br />
Estradiol) in Healthy Women: Drug-Drug<br />
Interaction Study Results —Bing Zhu, Karin<br />
Galil, Ivan Nestorov, Guolin Zhao, Venkata<br />
Meka, Jeanelle Kam, Sarah Sheikh<br />
P2.098 Lymphopenia in Patients with<br />
Multiple Sclerosis Treated with Delayed-<br />
Release Dimethyl Fumarate: Analysis<br />
of Two United States Electronic Health<br />
Record Databases —Madé Wenten, Teesta<br />
Soman, Cathy Lally, Maneesh Juneja, Susan<br />
Eaton, Claudia Prada, Anne Dilley<br />
P2.099 Characterization of Absolute<br />
Lymphocyte Count Profiles in MS Patients<br />
Treated with Delayed-Release Dimethyl<br />
Fumarate: Considerations for Patient<br />
Management —Robert Fox, Andrew Chan,<br />
Ralf Gold, J. Theodore Phillips, Krzysztof<br />
Selmaj, Ray Zhang, Ih Chang, Claudia Prada,<br />
Catherine Taylor, Jing Marantz<br />
P2.100 Quality Control of Autologous<br />
Bone Marrow Mesenchymal Stem Cell-<br />
Derived Neural Progenitors (MSC-NPs)<br />
from Patients with Multiple Sclerosis Prior<br />
to Intrathecal Injection —Tamara Vyshkina,<br />
Valentina Stefanova, Violaine Harris, Saud<br />
Sadiq<br />
P2.101 Longitudinal Data on<br />
Lymphopenia in Multiple Sclerosis<br />
Patients Treated with Dimethyl<br />
Fumarate —Meghan Romba, Annette<br />
Wundes, Gloria Von Geldern<br />
P2.102 A Longitudinal Study of JC<br />
Virus Serostatus Stability Among Multiple<br />
Sclerosis Patients —Raed Alroughani,<br />
Saeed Akhtar, Samar Ahmed, Jasem Al-<br />
Hashel<br />
P2.103 Fatal Autoimmune Hemolytic<br />
Anemia Associated with Alemtuzumab<br />
in a MS Patient with Severe Relapsing<br />
Remitting Disease Course and Prior<br />
Immune Therapies —Peter Rieckmann,<br />
Arne Lenz, Markus Hoffmann, Udo Poske,<br />
Karin Behr, Boris Kallmann<br />
P2.104 Defective Induction of<br />
Tolerogenic Myeloid DCs by IL-27 in<br />
Relapsing MS —Felipe Von Glehn Silva,<br />
Gopal Murugaiyan, Keren Regev, Chantal<br />
Kuhn, Radhika Raheja, Maria Antonietta<br />
Mazzola, Anu Paul, Sushrut Jangi, Pia<br />
Kivisakk, Roopali Gandhi, Howard Weiner<br />
P2.105 Role of Family Planning in<br />
Women of Child-Bearing Age with<br />
Multiple Sclerosis (MS) in Switzerland:<br />
Results of the Women with MS (WWMS)<br />
Patient Survey —Sarah Muehl, Stefanie<br />
Mueller, Adam Czaplinski, Petra Stellmes,<br />
Christian Kamm<br />
P2.106 Medication Adherence in<br />
Pediatric MS: Barriers and Facilitators —<br />
Stephanie Grover, Kim Edwards, Gulay Alper,<br />
Brenda Banwell, Petra Breiner, Mark Gorman,<br />
Jennifer Graves, Janace Hart, Timothy<br />
Lotze, Soe Mar, Lauren Mednick, Jayne<br />
Ness, Austin Noguera, Elizabeth Quon, Teri<br />
Schreiner, Carolyn Schwartz, Amy Waldman,<br />
Emmanuelle Waubant, Ruth Slater, E. Ann<br />
Yeh<br />
P2.107 Clinical Features of CNS-<br />
Autoimmunity After Allogeneic Bone<br />
Marrow Transplantation —Felix Bischof,<br />
Maria-Ioanna Stefanou<br />
MS and CNS Inflammatory Disease:<br />
Treatment Outcome Measures<br />
P2.108 Predicting Treatment Response<br />
to Teriflunomide in the TEMSO Study<br />
Using the Modified Rio Score —Maria<br />
Pia Sormani, Philippe Truffinet, Karthinathan<br />
Thangavelu, Pascal Rufi, Nicola De Stefano<br />
P2.109 Multiple Sclerosis and EDSS: A<br />
Walking Scale Standing on No Apparent<br />
Legs —Myassar Zarif, Karl Wissemann,<br />
Peter Marcote, Barbara Bumstead, Christina<br />
Burke, Lori Fafard, Smitha Thotam, Marijean<br />
Buhse, Jacob Sosnoff, Lisa Muratori, Mark<br />
Gudesblatt<br />
48 2016 AAN Annual Meeting Abstract Listing
Change language